After re-reading the last chairmans blog after the

Quote:

---

After re-reading the last chairmans blog after the "launch" of LYMPRO, I noticed that there was not any mention of " the first AD blood test on the market" only AMBS launches "their" first product

---

"We believe LymPro is poised to establish a market leading position as the first fundamental disease-biology based, blood biomarker test for Alzheimer's disease in the world , an area with significant unmet need and for which there has recently been a great deal of interest in the mainstream media."


" LymPro is the only Alzheimer's blood diagnostic with two independent peer-reviewed published articles (Stieler et al, NeuroReport, 2001 and Stieler et al, Neurobiology of Aging 2012). Amarantus announced further replication of this original work in October 2014, when the company reported interim data demonstrating high sensitivity and specificity in identifying Alzheimer's vs. non-Alzheimer's under two separate assay conditions. Amarantus anticipates reporting final top-line data of its LP-002 clinical study to assess LymPro's predictive value in diagnosing mild to severe Alzheimer's disease patients by the end of 2014. Amarantus intends to publish data from this study, as well as previously reported data, at prestigious scientific congresses and in peer-reviewed journals throughout the course of 2015 ."


http://ir.amarantus.com/company-news/detail/1...cal-trials